×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALLO – allogene therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALLO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/16
04:01 pm
allo
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
Low
Report
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
4/16
08:00 am
allo
Allogene Therapeutics (ALLO) was upgraded by JPMorgan Chase & Co. from "underweight" to "neutral".
Medium
Report
Allogene Therapeutics (ALLO) was upgraded by JPMorgan Chase & Co. from "underweight" to "neutral".
4/15
05:23 pm
allo
Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed? [Yahoo! Finance]
High
Report
Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed? [Yahoo! Finance]
4/15
08:30 am
allo
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
High
Report
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
4/14
09:50 pm
allo
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
Low
Report
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
4/14
11:46 am
allo
Allogene Therapeutics (ALLO) had its price target raised by Argus from $1.60 to $3.85. They now have a "market perform" rating on the stock.
High
Report
Allogene Therapeutics (ALLO) had its price target raised by Argus from $1.60 to $3.85. They now have a "market perform" rating on the stock.
4/14
08:57 am
allo
Allogene Therapeutics (ALLO) had its "market perform" rating reaffirmed by Sanford C. Bernstein.
High
Report
Allogene Therapeutics (ALLO) had its "market perform" rating reaffirmed by Sanford C. Bernstein.
4/14
08:44 am
allo
Allogene Therapeutics (ALLO) had its price target raised by Citizens Jmp from $5.00 to $8.00. They now have a "market outperform" rating on the stock.
High
Report
Allogene Therapeutics (ALLO) had its price target raised by Citizens Jmp from $5.00 to $8.00. They now have a "market outperform" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
3/12/2026
04:02 pm
allo
allogene therapeutics, inc.
BEAT
Report
-3.6%
allogene therapeutics, inc.
11/6/2025
04:05 pm
allo
allogene therapeutics, inc.
BEAT
Report
12.4%
allogene therapeutics, inc.
8/13/2025
04:05 pm
allo
allogene therapeutics, inc.
BEAT
Report
0.9%
allogene therapeutics, inc.
5/13/2025
04:05 pm
allo
allogene therapeutics, inc.
IN-LINE
Report
-16.4%
allogene therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/15
04:36 pm
allo
Form 8-K Allogene Therapeutics, For: Apr 14
High
Report
Form 8-K Allogene Therapeutics, For: Apr 14
4/15
04:33 pm
allo
Form 424B5 Allogene Therapeutics,
High
Report
Form 424B5 Allogene Therapeutics,
4/13
04:45 pm
allo
Form 424B5 Allogene Therapeutics,
High
Report
Form 424B5 Allogene Therapeutics,
4/13
04:09 pm
allo
Form 8-K Allogene Therapeutics, For: Apr 13
High
Report
Form 8-K Allogene Therapeutics, For: Apr 13
4/13
07:45 am
allo
Form 8-K Allogene Therapeutics, For: Apr 13
Low
Report
Form 8-K Allogene Therapeutics, For: Apr 13
4/2
04:48 pm
allo
Form 4 Allogene Therapeutics, For: Mar 31 Filed by: Beneski Benjamin Machinas
Medium
Report
Form 4 Allogene Therapeutics, For: Mar 31 Filed by: Beneski Benjamin Machinas
4/1
07:14 pm
allo
Form 144 Allogene Therapeutics, Filed by: Beneski Benjamin Machinas
Medium
Report
Form 144 Allogene Therapeutics, Filed by: Beneski Benjamin Machinas
3/18
04:07 pm
allo
Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Beneski Benjamin Machinas
Medium
Report
Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Beneski Benjamin Machinas
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/6
Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule
6.8%
3/18 Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Chang David D 6.8%
3/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.7%
4/23 Form DEF 14A Allogene Therapeutics, For: Dec 31 5.9%
4/28 Form 4 Allogene Therapeutics, For: Apr 24 Filed by: Chang David D 5.9%
4/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.5%
8/7 Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.0%
3/24 MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies 4.9%
3/13 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $35.00 price target on the stock. 4.7%
2/24 Form 4 Allogene Therapeutics, For: Feb 20 Filed by: SCHMIDT ERIC THOMAS 4.4%
3/18 Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Chang David D 6.8%
3/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.7%
4/23 Form DEF 14A Allogene Therapeutics, For: Dec 31 5.9%
4/28 Form 4 Allogene Therapeutics, For: Apr 24 Filed by: Chang David D 5.9%
4/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.5%
8/7 Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.0%
3/24 MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies 4.9%
3/13 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $35.00 price target on the stock. 4.7%
2/24 Form 4 Allogene Therapeutics, For: Feb 20 Filed by: SCHMIDT ERIC THOMAS 4.4%
TOP News Decliners
3/12
Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating.
-15.8%
11/6 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -6.4%
8/11 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -5.4%
8/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.2%
3/20 Senator Richard Burr Sold a Fortune in Stocks While Playing Down Coronavirus Threat [The New York Times] -5.1%
11/12 Allogene Moves Forward With CAR-T Therapy Pipeline [Seeking Alpha] -5.1%
4/1 Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences -4.9%
9/25 Form 4 Allogene Therapeutics, For: Sep 23 Filed by: Kazam Joshua A -4.8%
5/22 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at Stifel Nicolaus. They set a "hold" rating on the stock. -4.8%
11/5 Q3/2019 9/30/2019 EPS -0.500 ZacksConsensus -0.540 ActVsEst 0.040 - Beat -4.4%
11/6 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -6.4%
8/11 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -5.4%
8/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.2%
3/20 Senator Richard Burr Sold a Fortune in Stocks While Playing Down Coronavirus Threat [The New York Times] -5.1%
11/12 Allogene Moves Forward With CAR-T Therapy Pipeline [Seeking Alpha] -5.1%
4/1 Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences -4.9%
9/25 Form 4 Allogene Therapeutics, For: Sep 23 Filed by: Kazam Joshua A -4.8%
5/22 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at Stifel Nicolaus. They set a "hold" rating on the stock. -4.8%
11/5 Q3/2019 9/30/2019 EPS -0.500 ZacksConsensus -0.540 ActVsEst 0.040 - Beat -4.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: